In 2012, Newron completed Phase III clinical trials for safinamide, a
dual-mechanism a-aminoamide derivative, acting as an MAO-B and glutamate
release inhibitor (EPDA, press release, May 14, 2012). In 2006, Merck
Serono (a division of Merck KGaA) had acquired the exclusive worldwide
rights for safinamide; however, in 2011 the deal was terminated, seeing
Merck returning the compound to Newron due to concerns over the
potential market size for the drug.

Scope

Overview of Parkinson's disease, including epidemiology, etiology,
symptoms, diagnosis, pathology and treatment guidelines as well as an
overview on the competitive landscape.

Detailed information on Safinamide including product description,
safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for Safinamide for the top seven countries from 2012 to
2022.